Phase 2 Study of 9-ING-41, a Glycogen Synthase Kinase 3 Beta (GSK 3β) Inhibitor, Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma

9-ING-41 is a small molecule potent selective GSK-3β inhibitor with antitumor activity. This study investigates 9-ING-41 in combination with carboplatin chemotherapy in patients with incurable, recurrent or metastatic salivary gland carcinomas (SGC). Patients with advanced SGC (including all histologic subtypes and adenoid cystic carcinoma [ACC]) will receive 9-ING-41 intravenously (IV) along with carboplatin IV at standard dosing together on Day 1, and 9-ING-41 alone on Day 4 of a 21-day cycle. Participants will be enrolled to two histologic cohorts: Cohort 1 will be comprised of those with ACC, and Cohort 2 will include patients with non-ACC SGC (or all other salivary gland cancer histologies). Treatment will continue until progression of disease, death, or discontinuation of therapy for any reason.

开始日期2030-12-18

申办/合作机构

Actuate Therapeutics, Inc.初创企业

NCT05077800

/ Recruiting临床2期IIT

A Phase II Study of FOLFIRINOX Combined With the Glycogen Synthase Kinase-3 Beta (GSK-3 β) Inhibitor 9-ING-41 and the Transforming Growth Factor-β (TGF-β) Inhibitor Losartan in Patients With Untreated Metastatic Pancreatic Cancer

The purpose of this study is to find out if an experimental drug will prevent metastatic pancreatic adenocarcinoma from becoming resistant to standard treatment for the disease.
The names of the study drugs involved in this study are:
* 9-ING-41
* Losartan
* Ferumoxytol
* FOLFIRINOX (made up of 4 different drugs):
* 5-Fluorouracil (5-FU)
* Oxaliplatin
* Irinotecan
* Leucovorin

开始日期2022-03-21

申办/合作机构

Actuate Therapeutics, Inc.初创企业

[+1]

NCT05116800

/ Withdrawn临床2期IIT

A Phase 2 Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3β) Inhibitor, Combined With Chemotherapy in Advanced Soft Tissue and Bone Sarcomas

This is an open label, two-stratum, phase 2 clinical trial evaluating the efficacy of 9-ING-41 in combination with gemcitabine/docetaxel in patients ≥10 years of age with advanced sarcoma. 9-ING-41 in combination with gemcitabine and docetaxel will lead to sustained disease control and/or increase the rates of objective response in patients with unresectable or metastatic soft tissue and bone sarcomas.

开始日期2022-03-01

申办/合作机构

Brown University

[+1]

100 项与 Elraglusib 相关的临床结果

登录后查看更多信息

100 项与 Elraglusib 相关的转化医学

登录后查看更多信息

100 项与 Elraglusib 相关的专利（医药）

登录后查看更多信息

项与 Elraglusib 相关的文献（医药）

2024-11-01·Cancer research communications

Elraglusib Induces Cytotoxicity via Direct Microtubule Destabilization Independently of GSK3 Inhibition

Article

作者: Sutherland, Calum ; Tanaka, Tomoyuki U. ; Saurin, Adrian T. ; Li, Shuyu ; Tauro, Sudhir ; Coats, Josh T.

Abstract:

Elraglusib (9-ING-41) is an ATP-competitive inhibitor of glycogen synthase kinase-3 (GSK3) with preclinical studies demonstrating broad activity against many tumor types. Promising early-phase clinical trial data led to FDA orphan drug status, and a randomized phase II study in combination with cytotoxic chemotherapy in pancreatic cancer has recently completed its recruitment. Similarly, single-agent responses in adult T-cell leukemia/lymphoma and melanoma and combination treatment data in several other tumor types have been encouraging. The elraglusib mechanism of action is unknown, but it is unlikely to act through GSK3 inhibition because cytotoxicity is observed below the IC50 for GSK3, and other small molecule GSK3 inhibitors do not produce cytotoxic effects, at least in lymphoma cells. We show here that elraglusib perturbs chromosomal alignment to cause a mitotic arrest in multiple tumor lines. This arrest is caused by direct microtubule (MT) depolymerization, which prevents the attachment of kinetochores to MTs. At clinically relevant doses, these mitotically arrested cells eventually undergo mitotic slippage, leading to gross chromosome missegregation, DNA damage, and apoptosis. These effects explain the cytotoxicity of elraglusib because temporarily pausing cell-cycle progression with the CDK4/6 inhibitor palbociclib abolishes any drug-induced genotoxicity and apoptosis. In summary, elraglusib acts as a direct MT destabilizer both in vitro and across multiple cancer types, resulting in mitotic arrest, DNA damage, and apoptosis. These effects likely account for its broad pan-cancer activity, which does not rely upon GSK3 inhibition as they are not replicated by other GSK3 inhibitors.

Significance::

Elraglusib was designed as a GSK3 inhibitor and is currently in clinical trials for several cancers. We show conclusively that the target of elraglusib that leads to cytotoxicity is MTs and not GSK3. This has significant implications for ongoing clinical trials of the compound and will help in understanding off-target side effects, inform future clinical trial design, and facilitate the development of biomarkers to predict response.

2024-06-01·JHEP Reports

Glycogen synthase kinase 3 activity enhances liver inflammation in MASH

Article

作者: Islam, Shahidul ; Kim, Iljung ; Pavelko, Kevin D ; Mazar, Andrew P ; Li, Hu ; Warasnhe, Khaled ; Bamidele, Adebowale O ; Ibrahim, Samar H ; Noh, Yung-Kyun ; Kim Lee, Hyun Se ; Holmes, Heather ; Valenzuela-Pérez, Lucía ; Furuta, Kunimaro ; Guo, Qianqian ; Romero, Michael F ; Correia, Cristina ; Khoury, Mireille ; Sussman, Caroline R ; Meroueh, Chady ; Hirsova, Petra

Background & Aims:

Metabolic dysfunction-associated steatohepatitis (MASH) is characterized by excessive circulating toxic lipids, hepatic steatosis, and liver inflammation. Monocyte adhesion to liver sinusoidal endothelial cells (LSECs) and transendothelial migration (TEM) are crucial in the inflammatory process. Under lipotoxic stress, LSECs develop a proinflammatory phenotype known as endotheliopathy. However, mediators of endotheliopathy remain unclear.

Methods:

Primary mouse LSECs isolated from C57BL/6J mice fed chow or MASH-inducing diets rich in fat, fructose, and cholesterol (FFC) were subjected to multi-omics profiling. Mice with established MASH resulting from a choline-deficient high-fat diet (CDHFD) or FFC diet were also treated with two structurally distinct GSK3 inhibitors (LY2090314 and elraglusib [9-ING-41]).

Results:

Integrated pathway analysis of the mouse LSEC proteome and transcriptome indicated that leukocyte TEM and focal adhesion were the major pathways altered in MASH. Kinome profiling of the LSEC phosphoproteome identified glycogen synthase kinase (GSK)-3β as the major kinase hub in MASH. GSK3β-activating phosphorylation was increased in primary human LSECs treated with the toxic lipid palmitate and in human MASH. Palmitate upregulated the expression of C-X-C motif chemokine ligand 2, intracellular adhesion molecule 1, and phosphorylated focal adhesion kinase, via a GSK3-dependent mechanism. Congruently, the adhesive and transendothelial migratory capacities of primary human neutrophils and THP-1 monocytes through the LSEC monolayer under lipotoxic stress were reduced by GSK3 inhibition. Treatment with the GSK3 inhibitors LY2090314 and elraglusib ameliorated liver inflammation, injury, and fibrosis in FFC- and CDHFD-fed mice, respectively. Immunophenotyping using cytometry by mass cytometry by time of flight of intrahepatic leukocytes from CDHFD-fed mice treated with elraglusib showed reduced infiltration of proinflammatory monocyte-derived macrophages and monocyte-derived dendritic cells.

Conclusion:

GSK3 inhibition attenuates lipotoxicity-induced LSEC endotheliopathy and could serve as a potential therapeutic strategy for treating human MASH.

Impact and Implications:

LSECs under lipotoxic stress in MASH develop a proinflammatory phenotype known as endotheliopathy, with obscure mediators and functional outcomes. The current study identified GSK3 as the major driver of LSEC endotheliopathy, examined its pathogenic role in myeloid cell-associated liver inflammation, and defined the therapeutic efficacy of pharmacological GSK3 inhibitors in murine MASH. This study provides preclinical data for the future investigation of GSK3 pharmacological inhibitors in human MASH. The results of this study are important to hepatologists, vascular biologists, and investigators studying the mechanisms of inflammatory liver disease and MASH, as well as those interested in drug development.

2024-02-01·Clinical cancer research : an official journal of the American Association for Cancer Research

Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3β Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies

Article

作者: Cervantes, Andrés ; Cavalcante, Ludimila ; Munster, Pamela ; Borden, Brittany A. ; Harvey, R. Donald ; Powell, Steven ; Longstreth, James ; Coveler, Andrew L. ; Mikrut, William ; Mazar, Andrew P. ; Giles, Francis J. ; Kurzrock, Razelle ; Weisskittel, Taylor ; Li, Hu ; Koukol, Austin ; Smith, Sheri ; Bastos, Bruno ; Sahai, Vaibhav ; Steeghs, Neeltje ; Ma, Wen Wee ; Carneiro, Benedito A. ; Safran, Howard ; Davis, Elizabeth ; Mahalingam, Devalingam ; Sahebjam, Solmaz ; Saeed, Anwaar

Abstract:

Purpose::

The safety, pharmacokinetics, and efficacy of elraglusib, a glycogen synthase kinase-3β (GSK-3β) small-molecule inhibitor, as monotherapy or combined with chemotherapy, in patients with relapsed or refractory solid tumors or hematologic malignancies was studied.

Patients and Methods::

Elraglusib (intravenously twice weekly in 3-week cycles) monotherapy dose escalation was followed by dose escalation with eight chemotherapy regimens (gemcitabine, doxorubicin, lomustine, carboplatin, irinotecan, gemcitabine/nab-paclitaxel, paclitaxel/carboplatin, and pemetrexed/carboplatin) in patients previously exposed to the same chemotherapy.

Results::

Patients received monotherapy (n = 67) or combination therapy (n = 171) elraglusib doses 1 to 15 mg/kg twice weekly. The initial recommended phase II dose (RP2D) of elraglusib was 15 mg/kg twice weekly and was defined, without dose-limiting toxicity observation, due to fluid volumes necessary for drug administration. The RP2D was subsequently reduced to 9.3 mg/kg once weekly to reduce elraglusib-associated central/peripheral vascular access catheter blockages. Other common elraglusib-related adverse events (AE) included transient visual changes and fatigue. Grade ≥3 treatment-emergent AEs occurred in 55.2% and 71.3% of patients on monotherapy and combination therapy, respectively. Part 1 monotherapy (n = 62) and part 2 combination (n = 138) patients were evaluable for response. In part 1, a patient with melanoma had a complete response, and a patient with acute T-cell leukemia/lymphoma had a partial response (PR). In part 2, seven PRs were observed, and the median progression-free survival and overall survival were 2.1 [95% confidence interval (CI), 2–2.6] and 6.9 (95% CI, 5.7–8.4) months, respectively.

Conclusions::

Elraglusib had a favorable toxicity profile as monotherapy and combined with chemotherapy and was associated with clinical benefit supporting further clinical evaluation in combination with chemotherapy.

项与 Elraglusib 相关的新闻（医药）

2025-01-08

·Pharmaceutical Technology

EMA gives OMPD to Actuate’s pancreatic cancer therapy

Elraglusib is aimed at treating pancreatic ductal adenocarcinoma. Credit: Jo Panuwat D/Shutterstock. Actuate Therapeutics has gained orphan medicinal product designation (OMPD) from the European Medicines Agency (EMA) for elraglusib to treat pancreatic ductal adenocarcinoma (PDAC). The glycogen synthase kinase-3 beta (GSK-3β) inhibitor elraglusib is being studied as a first-line therapy in combination with gemcitabine/nab-paclitaxel (GnP) in individuals with metastatic pancreatic cancer (mPDAC). The randomised Actuate-1801 Part 3β trial is comparing this combination to GnP alone. The Phase II trial’s interim analysis revealed a one-year survival rate increase with a p-value of 0.002 and a median overall survival with a hazard ratio of 0.63 and a p-value of 0.016, favouring the elraglusib combination. Actuate Therapeutics CEO and president Daniel Schmitt stated: “This regulatory milestone, along with the recently announced positive interim results from our Phase II trial of elraglusib in patients with mPDAC that showed a significant clinical benefit and anti-tumour activity, should expedite our efforts to advance elraglusib as a novel, potential treatment for mPDAC. “We look forward to reporting topline data from our Phase II trial in 1H 2025 and working closely with the EMA and the FDA [US Food and Drugs Administration] to accelerate elraglusib’s clinical development programme in metastatic pancreatic cancer.” Elraglusib, the company’s lead investigational candidate, targets molecular pathways that promote tumour growth and resistance to conventional cancer treatments, including several DNA damage response (DDR) pathways. It is tailored to mediate anti-tumour immunity by inhibiting nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) and regulating several immune checkpoints and immune cell functions. EMA orphan designation is awarded to therapies for life-threatening or chronically debilitating diseases that affect no more than two in 10,000 individuals in the European Union (EU) and for which there is no satisfactory therapy.

临床结果孤儿药临床2期免疫疗法

2025-01-07

·GlobeNewswire-Health Care

Actuate Therapeutics Receives EMA Orphan Medicinal Product Designation for Elraglusib for the Treatment of Pancreatic Cancer

CHICAGO and FORT WORTH, Texas, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced that the European Medicines Agency (EMA) has granted Orphan Medicinal Product Designation (OMPD) to elraglusib, a novel GSK-3β inhibitor, for the treatment of pancreatic ductal adenocarcinoma (PDAC). “With limited treatment options available for patients with PDAC, the EMA Orphan Drug Designation and FDA Orphan Drug Designation granted to elraglusib for the same indication reflect elraglusib’s potential to address a critical need for people living with this aggressive disease with a notably poor prognosis. This regulatory milestone, along with the recently announced positive interim results from our Phase 2 trial of elraglusib in patients with mPDAC that showed a significant clinical benefit and anti-tumor activity, should expedite our efforts to advance elraglusib as a novel, potential treatment for mPDAC,” said Daniel Schmitt, President & Chief Executive Officer of Actuate. “We look forward to reporting topline data from our Phase 2 trial in 1H 2025 and working closely with the EMA and the FDA to accelerate elraglusib’s clinical development program in metastatic pancreatic cancer.” Elraglusib is a novel GSK-3β inhibitor currently in a randomized Phase 2 trial (Actuate-1801 Part 3B study, NCT03678883) comparing the combination of elraglusib with gemcitabine/nab-paclitaxel (GnP) to GnP alone as a first line therapy in patients with metastatic pancreatic cancer (mPDAC). A recently reported analysis of interim Phase 2 data demonstrated that treatment with the elraglusib combination led to statistically significant increases in 1-year survival rate (p value of 0.002) and median overall survival (hazard ratio of 0.63, p value of 0.016) versus treatment with GnP alone. Orphan Designation is granted to therapies intended for the treatment, prevention, or diagnosis of life-threatening or chronically debilitating diseases that affect no more than two in 10,000 people in the European Union (EU) and for which no satisfactory therapy is available. The treatment must also provide significant benefit to those affected by the condition. EMA orphan drug designation provides certain benefits, including the potential for 10 years of market exclusivity following regulatory approval in the EU, reduction in regulatory fees and a centralized EU approval process1. 1. European Medicines Agency, "Orphan Designation." https://www.ema.europa.eu/en/human-regulatory-overview/orphan-designation-overview About Actuate Therapeutics, Inc. Actuate is a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers. Actuate’s lead investigational drug product, elraglusib (a novel GSK-3β inhibitor), targets molecular pathways in cancer that are involved in promoting tumor growth and resistance to conventional cancer drugs such as chemotherapy including several DNA Damage Response (DDR) pathways. Elraglusib is designed to act as a mediator of anti-tumor immunity through the inhibition of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) and regulates multiple immune checkpoints and immune cell function. For additional information, please visit the Company’s website at http://www.actuatetherapeutics.com. Forward-Looking Statements This press release contains forward-looking statements about us, including our clinical trials and development plans, and our industry. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would,” or the negative of these terms or other comparable terminology are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. All statements, other than statements related to present facts or current conditions or of historical facts, contained in this press release are forward-looking statements. Accordingly, these statements involve estimates, assumptions, substantial risks and uncertainties which could cause actual results to differ materially from those expressed in them, including but not limited to that clinical and preclinical drug development involves a lengthy and expensive process with uncertain timelines and outcomes, results of prior preclinical studies and early clinical trials are not necessarily predictive of future results, and elraglusib may not achieve positive clinical results or favorable preclinical results or receive regulatory approval on a timely basis, if at all; that we may not successfully enroll additional patients or establish or advance plans for further development, including through conversations with the FDA or EMA and the standards such bodies may impose for such development; that elraglusib could be associated with side effects, adverse events or other properties or safety risks, which could delay or preclude regulatory approval, cause us to suspend or discontinue clinical trials or result in other negative consequences; preliminary and unpublished data may be subject to change following the availability of more data or following a more comprehensive review of the data and should not be relied upon as a final analysis; our reliance on third parties to conduct our non-clinical studies and our clinical trials; our reliance on third-party licensors and ability to preserve and protect our intellectual property rights; that we face significant competition from other biotechnology and pharmaceutical companies; our ability to fund development activities; and our ability to realize any benefits or value associated with the Orphan Medicinal Product Designation (OMPD) granted to elraglusib by the EMA for the treatment of pancreatic ductal adenocarcinoma (PDAC). In addition, any forward-looking statements are qualified in their entirety by reference to the factors discussed under the heading “Item 1A. Risk Factors” in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 filed with the SEC on November 13, 2024 and other filings with the SEC. Because the risk factors referred to above could cause actual results or outcomes to differ materially from those expressed in any forward-looking statements made by us or on our behalf, you should not place undue reliance on any forward-looking statements. Further, any forward-looking statement speaks only as of the date on which it is made. New factors emerge from time to time, and it is not possible for us to predict which factors will arise. In addition, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Unless legally required, we do not undertake any obligation to release publicly any revisions to such forward-looking statements to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events. Investor Contact Mike MoyerManaging DirectorLifeSci Advisors, LLCmmoyer@lifesciadvisors.com

孤儿药临床结果临床2期

2024-12-18

·医学新视点

“癌症之王”靶病灶100%缩小！创新疗法为患者带来新选择

▎药明康德内容团队编辑 Actuate Therapeutics日前公布其在研GSK-3β小分子抑制剂elraglusib联合吉西他滨/白蛋白紫杉醇（GnP），用于转移性胰腺导管腺癌（mPDAC）一线治疗2期试验Actuate-1801 Part 3B的积极结果。 Actuate-1801 Part 3B研究是一项随机对照的2期临床试验，旨在评估elraglusib联合GnP与GnP单独相比，作为mPDAC一线治疗中的疗效和安全性。该研究共纳入286例未接受过系统性治疗的mPDAC患者，按2：1的比例随机分配至elraglusib联合治疗组（elraglusib + GnP）或对照组（GnP单独治疗）。中期数据分析显示，试验达成主要终点。Elraglusib联合治疗组患者的1年生存率为43.6%，显著高于活性对照组的22.5%（p=0.002）。其中elraglusib联合治疗组患者的18个月与24个月生存率分别为20.9%和16.7%，而活性对照组则皆为0%。Elraglusib联合治疗组患者的死亡风险降低了37%，中位总生存期（mOS）显著延长至9.3个月，而活性对照组患者的mOS则为7.2个月（HR=0.63，p=0.016）。 ▲Actuate Therapeutics管线图（图片来源：Actuate Therapeutics公司官网）截至2024年11月15日，elraglusib联合治疗组与活性对照组患者的客观缓解率（ORR）分别为27.7%与20.5%；疾病控制率（DCR）分别为42.6%与33.3%；无进展生存期（PFS）分别是5.6个月与4.9个月。值得一提的是，elraglusib联合治疗组中有2例原本不可手术的患者，经过治疗后靶病灶明显缩小，成功接受了手术切除，其中1例在手术后达到了100%肿瘤负荷清除。此外，该组还观察到1例完全缓解（CR）和1例部分缓解（PR），两者均实现了靶病灶100%缩小，而对照组未出现类似结果。安全性方面，试验达到了主要的安全性终点。Elraglusib联合治疗组的不良事件（TEAEs）和严重不良事件（SAEs）与活性对照组相似，显示出良好的风险-获益特征。 Elraglusib（9-ING-41）是一种选择性的强效GSK-3β抑制剂，已在临床试验中显示出积极的抗癌活性。目前，elraglusib正在开发用于治疗mPDAC。在临床前模型中，elraglusib表现出免疫调节作用，并在临床样本中显示出对血清细胞因子谱的调节能力。相关阅读减少化疗，疗效相当，还更安全！《柳叶刀》子刊：转移性胰腺癌新治疗策略《柳叶刀》子刊：胰腺癌获突破性进展！溶瘤病毒疗法安全可行医科院肿瘤医院：每16人就有1人会死于消化系统癌症参考资料： [1] Actuate Therapeutics Announces Positive Interim Phase 2 Data of Elraglusib in First Line Treatment of Metastatic Pancreatic Cancer. Retrieved December 17, 2024 from https://www.globenewswire.com/news-release/2024/12/17/2998209/0/en/Actuate-Therapeutics-Announces-Positive-Interim-Phase-2-Data-of-Elraglusib-in-First-Line-Treatment-of-Metastatic-Pancreatic-Cancer.html [2] 2024-ASCO-Identification of immune biomarkers in treatment-naive patients with metastatic pancreatic cancer treated with the GSK-3 inhibitor elraglusib (9-ING-41) in combination with gemcitabine/nab-paclitaxel in the 1801 phase 2 study. Retrieved December 17, 2024 from https://actuatetherapeutics.com/wp-content/uploads/2024/09/Weiskittel-Publication-Pancreatic-cancer-ASCO-2024.pdf 免责声明：药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。版权说明：本文来自药明康德内容团队，欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。分享，点赞，在看，传递医学新知

临床结果临床2期

100 项与 Elraglusib 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB16047

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
转移性黑色素瘤	临床2期	美国	Actuate Therapeutics, Inc.初创企业	2023-05-31
转移性黑色素瘤	临床2期	美国	Lantern Pharma, Inc.	2023-05-31
转移性胰腺腺癌	临床2期	美国	Actuate Therapeutics, Inc.初创企业	2022-03-21
胰腺继发性恶性肿瘤	临床2期	美国	Actuate Therapeutics, Inc.初创企业	2022-03-21
尤文肉瘤	临床2期	美国	Actuate Therapeutics, Inc.初创企业	2022-03-01
转移性骨肉瘤	临床2期	美国	Actuate Therapeutics, Inc.初创企业	2022-03-01
晚期胰腺腺癌	临床2期	美国	Actuate Therapeutics, Inc.初创企业	2022-01-26
晚期胰腺腺癌	临床2期	美国	Incyte Corp.	2022-01-26
胰腺导管腺癌	临床2期	美国	Incyte Corp.	2022-01-26
胰腺导管腺癌	临床2期	美国	Actuate Therapeutics, Inc.初创企业	2022-01-26

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04239092 (Actuate-1801, GlobeNewswire) 人工标引	临床2期	胰腺癌一线	286	Elraglusib + gemcitabine/nab-paclitaxel	網繭衊範積網膚夢餘繭(積憲積選餘積鑰獵簾獵) = 壓蓋淵憲襯廠餘廠艱獵製繭構製鏇餘範糧蓋糧 (範壓蓋廠壓築願衊簾簾 ) 达到更多	积极	2024-12-17
NCT04239092 (Actuate-1801, GlobeNewswire) 人工标引	临床2期	胰腺癌一线	286	gemcitabine/nab-paclitaxel	網繭衊範積網膚夢餘繭(積憲積選餘積鑰獵簾獵) = 壓艱遞獵衊壓構艱製觸製繭構製鏇餘範糧蓋糧 (範壓蓋廠壓築願衊簾簾 ) 达到更多	积极	2024-12-17
NCT03678883 (ASCO 12023 \| ASCO 22023) 人工标引	临床2期	晚期胰腺导管腺癌	42	gemcitabine+Albumin-Bound Paclitaxel+Elraglusib	夢齋鬱襯淵鹽範鑰顧膚(夢築齋壓艱鹽糧淵衊範) = 壓鬱襯願積築製網遞蓋夢蓋簾鬱願膚糧遞壓選 (願築淵範淵夢製衊鹹衊, 32.5 ~ 70.6) 更多	积极	2023-05-26
NCT03678883 (AACR2023) 人工标引	临床1/2期	晚期癌症三线	-	elraglusib (melanoma)	衊觸獵繭襯構構憲窪壓(壓觸顧衊壓窪壓夢壓襯) = 鏇選糧蓋醖築選選壓鹽鏇衊鹹願構餘鹽淵廠顧 (觸觸獵網夢鏇築網憲鹹 )	积极	2023-04-14
NCT03678883 (AACR2023) 人工标引	临床1/2期	晚期癌症三线	-	elraglusib (colorectal cancer)	顧鑰壓製選膚構淵鏇窪(衊襯糧壓鹽艱窪糧壓憲) = 鑰憲築鹽築鹹窪餘觸鏇鹽齋窪鬱夢顧鏇艱襯選 (觸壓窪鹹醖窪蓋窪糧獵 ) 更多	积极	2023-04-14
NCT04239092 (ASCO2022) 人工标引	临床1/2期	肿瘤	23	ElraglusibElraglusib alone or in combination with chemotherapy	簾願遞憲觸網鏇淵獵憲(醖膚積鹽顧範鹹網憲積) = none 齋襯廠鹽衊壓糧艱壓壓 (顧簾鏇遞構顧衊願範鬱 ) 更多	积极	2022-06-02
NCT04239092 (ASCO2022) 人工标引	临床1/2期	肿瘤	23	Elraglusib + cyclophosphamide/topotecan or irinotecan	簾願遞憲觸網鏇淵獵憲(醖膚積鹽顧範鹹網憲積) = none 齋襯廠鹽衊壓糧艱壓壓 (顧簾鏇遞構顧衊願範鬱 ) 更多	积极	2022-06-02
NCT03678883 (Pubmed) 人工标引	临床1/2期	肿瘤 \| 脑恶性胶质瘤	18	Lomustine+Elraglusib	積齋選鹹膚鹽衊網鹹壓(遞遞淵鏇艱壓糧壓繭壓) = mild vision changes 50%, infusion reactions 22% 廠膚壓鏇積餘範鹹壓夢 (餘窪範鏇糧淵鹽憲鏇襯 ) 更多	积极	2022-02-07
NCT03678883 (ACTUATE 1801, SNO2021)	临床1/2期	胶质瘤 IDH \| 1p19q \| MGMT ... 更多	18	9-ING-41 monotherapy	繭遞餘淵構襯窪顧襯選(夢艱齋鹹襯夢壓積廠網) = 簾網範艱窪鏇積衊艱積衊襯網憲憲遞願鹽壓糧 (餘顧艱醖製壓廠鑰窪襯 ) 更多	积极	2021-11-12
NCT03678883 (ACTUATE 1801, SNO2021)	临床1/2期	胶质瘤 IDH \| 1p19q \| MGMT ... 更多	18	9-ING-41 + Lomustine	齋鏇蓋網襯獵夢鏇範壓(獵製獵鏇夢淵構鏇窪鏇) = 餘艱齋醖膚鏇鹹糧選糧壓遞顧簾廠餘壓網鑰夢 (鏇築夢廠糧製繭範遞鑰 ) 更多	积极	2021-11-12
AACR2021	N/A	结直肠癌	-	9-ING-41	積顧積膚蓋選鑰遞淵憲(艱鏇鬱鹹壓製網網齋鏇) = 顧範鹹積鹹鹽願獵構憲遞鹽繭鹹製淵顧廠鬱鹽 (糧艱繭廠鑰淵範觸構選 ) 更多	-	2021-07-01
NCT03678883 (ASCO 12021 \| ASCO 22021) 人工标引	临床1/2期	实体瘤 \| 脑恶性胶质瘤 \| 难治性血液恶性肿瘤	227	lomustine+9-ing-41	鏇選蓋範糧遞膚窪鹽選(簾襯構蓋鏇構鬱製製鑰) = 鬱鏇築構餘醖壓鏇鬱膚製襯鑰構鑰選鹽製衊觸 (夢鑰窪簾衊觸壓網築鏇 ) 更多	积极	2021-05-28
NCT03678883 (ASCO2020)	临床1期	肿瘤	101	9-ING-41 combined with chemotherapy	範簾鹽鏇範衊鹹鬱鹽鹽(艱築鹹鬱艱衊繭糧鹽鹽) = n = 14 餘膚遞鑰構觸獵獵鹹繭 (選鏇鬱積襯構積網積願 ) 更多	积极	2020-05-25
NCT04218071 \| NCT03678883 \| NCT04239092 (Pubmed \| Anticancer Drugs)	临床1/2期	神经母细胞瘤	17	9-ING-41	鏇餘遞鬱積選壓獵簾築(蓋鑰顧顧醖鑰糧淵遞餘) = 範觸鏇鑰範築窪夢繭糧顧廠醖鏇夢網選鹽衊獵 (餘壓願願鬱網膚鬱夢鏇 )	-	2018-09-01